Ribena is a brand of blackcurrant-based soft drink, and fruit drink concentrate designed to be mixed with water. It is available in bottles, cans and multi-packs. Originally of English origin, it was produced by the pharmaceutical company GlaxoSmithKline (GSK) until 2013, when the brand was sold to Japanese beverage conglomerate Suntory.
GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth largest pharmaceutical company and #294 on the 2022 Fortune Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck Sharp & Dohme.
Horlicks is a sweet malted milk hot drink powder developed by founders James and William Horlick. It was first sold as "Horlick's Infant and Invalids Food", soon adding "aged and travellers" to their label. In the early 20th century, it was sold as a powdered meal replacement drink mix.
Lucozade is a British brand of soft drinks and energy drinks manufactured and marketed by the Japanese company Suntory. Created as "Glucozade" in the UK in 1927 by a Newcastle pharmacist, William Walker Hunter, it was acquired by the British pharmaceutical company Beecham's in 1938 and sold as Lucozade, an energy drink for the sick. Its advertising slogan was "Lucozade aids recovery". It was sold mostly in pharmacies up until the 1980s before it was more readily available as a sports drink in shops across the UK.
Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.
Cepacol is an American brand of personal hygiene products, as well as for relief of sore throat. It is distributed in the US by Reckitt. The brand was originally owned by J.B. Williams. Following acquisition by Combe Incorporated, Combe Incorporated sold Cepacol to Reckitt Benckiser in 2011.
Goody's Powder, also called Goody's Headache Powders, is an over-the-counter aspirin/paracetamol/caffeine–based pain reliever, in single-dose powder form, which is marketed and sold by Prestige Brands. The powder delivery saves the time needed for the patient's digestive system to break down a tablet or capsule, ostensibly causing the medication to work faster. Goody's Extra Strength Powder consists of aspirin, caffeine, and paracetamol (acetaminophen) in a formula identical to that of Excedrin, a product of Novartis, but in the no-digestion-needed powder form.
Actifed is a registered trademark for a combination antihistamine and nasal decongestant medication used for cold and allergy symptoms. Actifed was developed in 1958 by Burroughs Wellcome & Company, later Haleon.
Germolene is the brand name used on a range of antiseptic products produced by the Bayer company, who purchased the brand from SmithKline Beecham in 1999. It is manufactured for Bayer UK by the Devon-based Wrafton Laboratories division of US over-the counter and supermarket own-label preparation producer Perrigo.
Sensodyne is a brand name of toothpaste and mouthwash targeted at people with sensitive teeth. Sensodyne is owned by Haleon and is marketed under the name Shumitect in Japan.
The Beecham Group plc was a British pharmaceutical company. It was once a constituent of the FTSE 100 Index. Founded by Thomas Beecham who opened the first factory in St Helens, Lancashire in 1859, Beecham focused on marketing the business by advertising in newspapers and using a network of wholesale agents in northern England and in London, rapidly building up the business. In August 1859 he created the slogan for Beecham's Pills: "Worth a guinea a box", considered to be the world's first advertising slogan, which helped the business become a global brand.
NiQuitin is a range of nicotine replacement products designed to help smokers quit by replacing the nicotine supplied by cigarettes with a lower, steadier level in order to relieve withdrawal. This is to help users wean off nicotine gradually. Nicotine replacement therapy products are indicated as temporary aids for the cigarette smoker who wants to give up smoking. They serve as alternative sources of nicotine and provide relief of nicotine withdrawal symptoms in nicotine-dependent individuals who are acutely withdrawing from cigarette smoking.
S. E. Massengill Company was a pharmaceutical company founded in 1898 by Samuel Evans Massengill, who graduated from the University of Nashville Medical School but decided to manufacture drugs rather than practice medicine himself. By 1937, it employed more than two hundred people in Bristol, Tennessee, including six graduate pharmaceutical chemists. In 2011, it was purchased by Prestige Brands, now known as Prestige Consumer Healthcare.
The pharmaceutical industry in the United Kingdom directly employs around 73,000 people and in 2007 contributed £8.4 billion to the UK's GDP and invested a total of £3.9 billion in research and development. In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.
Pharmaceutical fraud involves activities that result in false claims to insurers or programs such as Medicare in the United States or equivalent state programs for financial gain to a pharmaceutical company. There are several different schemes used to defraud the health care system which are particular to the pharmaceutical industry. These include: Good Manufacturing Practice (GMP) Violations, Off Label Marketing, Best Price Fraud, CME Fraud, Medicaid Price Reporting, and Manufactured Compound Drugs. Examples of fraud cases include the GlaxoSmithKline $3 billion settlement, Pfizer $2.3 billion settlement, and Merck $650 million settlement. Damages from fraud can be recovered by use of the False Claims Act, most commonly under the qui tam provisions which rewards an individual for being a "whistleblower", or relator (law).
United States v. GlaxoSmithKline was a case before the United States District Court for the Eastern District of Pennsylvania. Robert J. Merena was one of the first who filed claims against SmithKline Beecham Clinical Laboratories on November 12, 1993. The complaints alleged that GlaxoSmithKline, which operated a system of clinical laboratories, adopted myriad complicated procedures for the purpose of defrauding state and federal healthcare programs, in particular Medicare and Medicaid. The U.S. Justice Department publicly praised Robert Merena for his "cooperation and support" in helping the government collect the largest settlement ever involving a whistle-blower lawsuit. The SmithKline settlement is considered to be one of the largest whistleblower assisted recoveries in the history of the United States.
Study 329 was a clinical trial which was conducted in North America from 1994 to 1998 to study the efficacy of paroxetine, an SSRI anti-depressant, in treating 12- to 18-year-olds diagnosed with major depressive disorder. Led by Martin Keller, then professor of psychiatry at Brown University, and funded by the British pharmaceutical company SmithKline Beecham—known since 2000 as GlaxoSmithKline (GSK)—the study compared paroxetine with imipramine, a tricyclic antidepressant, and placebo. SmithKline Beecham had released paroxetine in 1991, marketing it as Paxil in North America and Seroxat in the UK. The drug attracted sales of $11.7 billion in the United States alone from 1997 to 2006, including $2.12 billion in 2002, the year before it lost its patent.
Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including ChapStick lip balm, Sensodyne toothpaste, Panadol and Advil painkillers and Centrum vitamins. The company is a global leader in over the counter medicines with a 7.3 percent market share.
(what is this?) (verify) 
